All In Biotech

Drug Trial Radar · NCT05539651

A Single and Multiple Ascending Doses Study to Evaluate the Safety and Pharmacokinetics of RBD5044

A Randomized, Double-Blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of Subcutaneously Administered RBD5044 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Dec 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Nov 10, 2022

Primary completion

Oct 30, 2024

Study completion Oct 30, 2024

Sponsor

Sponsor type
Industry
First posted
Sep 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled phase I study to evaluate the safety, tolerability, PK profiles and PD effect of single and multiple ascending doses of subcutaneously administered RBD5044 in healthy subjects. The study will be performed in 2 phases: single ascending dose (SAD) phase and multiple ascending doses (MAD) phase in healthy subjects. There are 6 cohorts in SAD phases, the dose levels are 5mg, 20mg, 60mg, 90mg, 120mg and 150mg. There are 3 cohorts in MAD phases, the dose levels are 60mg, 90mg and 120mg.The decision to escalate to subsequent dose levels will be made by the SRC based on the review of all available safety information, including AEs, ECGs, vital signs, and clinical laboratory test results in each cohort.

Conditions

  • Health Volunteer

Interventions

  • RBD5044Drug

    Subcutaneously Administered RBD5044 in Healthy Subjects

  • PlaceboDrug

    Subcutaneously Administered Placebo in Healthy Subjects

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v5.0Time frame: SAD: Up to 24 weeks; MAD: Up to 28 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Q-Pharm Pty Limited

    Brisbane, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.